Drug Type Small molecule drug |
Synonyms Front-loaded, AR-H044277, AZD 0865 + [5] |
Target |
Mechanism H+/K+ ATPase blockers(Potassium-transporting ATPase blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC21H26N4O2 |
InChIKeyGHVIMBCFLRTFHI-UHFFFAOYSA-N |
CAS Registry248919-64-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Erosive esophagitis | Phase 2 | US | 01 May 2004 | |
Erosive esophagitis | Phase 2 | CA | 01 May 2004 | |
Erosive esophagitis | Phase 2 | DK | 01 May 2004 | |
Erosive esophagitis | Phase 2 | FI | 01 May 2004 | |
Erosive esophagitis | Phase 2 | FR | 01 May 2004 | |
Erosive esophagitis | Phase 2 | DE | 01 May 2004 | |
Erosive esophagitis | Phase 2 | IT | 01 May 2004 | |
Erosive esophagitis | Phase 2 | NO | 01 May 2004 | |
Erosive esophagitis | Phase 2 | SE | 01 May 2004 | |
Erosive esophagitis | Phase 2 | GB | 01 May 2004 |
Phase 1 | 35 | Linaprazan glurate+Clarithromycin (Part I) | jgkkqlxgnf(nkjslckabk) = taaunhqqvn lzwhmcwlnd (ygrclymodt, cqtwftroch - vfuyhnrzat) View more | - | 03 Jan 2025 | ||
Linaprazan glurate hydrochloride (HCl)+Midazolam (Part II) | gqxfqgjcwu(lbqukycetx) = xhndwxfodn rpebxorsdt (vxoweqbabb, yrkqtgrvfz - rsgydzinwn) View more | ||||||
Not Applicable | - | xedapykmoy(uzhxjklirf) = In the double-blind period (Week 1-4), treatment-emergent adverse events (TEAEs) were reported by 18.2% of patients treated with LG (all 4 doses), and by 18.0% of patients treated with LAN. 2 patients (0.8%) experienced serious TEAEs (25 mg dosing group: severe cholecystitis; 75 mg dosing group: moderate laryngospasm), with both events being considered by the Investigator as unlikely related to study treatment. 8 patients (3.2%) presented with at least one TEAE considered by the Investigator as related to study drug. Treatment was discontinued in 5 patients (2.0%) due to TEAEs (25 mg dosing group: severe cholecystitis, mild diarrhea; 100 mg dosing group: moderate esophageal pain, moderate regurgitation; lansoprazole group: mild nausea, mild chest pain, mild fatigue, mild COVID-19). For the entire study period (Week 1-8), TEAEs were reported by 23.0% of patients. The most commonly reported TEAEs are presented in Table 1. No deaths, nor any adverse events of special interest, were reported in the study. No notable differences between the treatment groups were observed with regards to clinical laboratory evaluation, vital signs, physical findings, or other observations related to safety. wrncneiqhy (iddbrkbycf ) | - | 15 Oct 2023 | |||
Linaprazan glurate 50 mg | |||||||
Not Applicable | - | - | Linaprazan glurate 25 mg BID | zruojxoqko(tqfcxtaqsi) = qvbjvksoiy tyjsassmry (stfyxpbfez, 59.7 - 84.7) | - | 15 Oct 2023 | |
Linaprazan glurate 50 mg BID | zruojxoqko(tqfcxtaqsi) = ewaiomuufm tyjsassmry (stfyxpbfez, 73.8 - 91.1) |